Baylor University Medical Center Proceedings April 2014, Volume 27, Number 2 | Page 53

1.

2.

3.

4.

Carbone A, Gloghini A, Aiello A, Testi A, Cabras A. B-cell lymphomas
with features intermediate between distinct pathologic entities. From
pathogenesis to pathology. Hum Pathol 2010;41(5):621–631.
Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans
HC, Boerma EJ, Kluin PM. Double-hit B-cell lymphomas. Blood
2011;117(8):2319–2331.
Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura
S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S,
Hayashi T, Ishigatsubo Y, Miura I. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.
Haematologica 2009;94(7):935–943.
Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P,
Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR. B-cell lymphomas with

5.

6.
7.

8.

concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms
with clinical and pathologic features distinct from Burkitt lymphoma and
diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34(3):327–340.
de Jong D. Novel lymphoid neoplasms—the borderland between
diffuse large B-cell lymphoma and Burkitt’s lymphoma. Haematologica
2009;94(7):894–896.
Tomita N. BCL2 and MYC dual-hit lymphoma/leukemia. J Clin Exp
Hematop 2011;51(1):7–12.
Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C.
Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms. Genes Chromosomes Cancer 2011;50(1):43–50.
Motlló C, Grau J, Juncà J